ReviewExpert opinion on pharmacotherapy2020
The limits and challenges of antiobesity pharmacotherapy.
Review in Expert opinion on pharmacotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 62 citations in OpenAlex.
- Combination Pharmacotherapies for Obesity-Current Evidence and Future Directions.Endocrinology, diabetes & metabolism · 2026Review
- Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey.BMC primary care · 2026Article
- Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions.Food science & nutrition · 2026Review
- A multidisciplinary approach to weight management and reproductive care: a retrospective cohort study on weight loss through personalized and patient-centered care.Reproductive biology and endocrinology : RB&E · 2025Article
- Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study.Obesity (Silver Spring, Md.) · 2025Observational
- Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.Current diabetes reports · 2025Review
- Anti-obesity treatment preferences of healthcare providers and people living with obesity: A survey-based study.Clinical obesity · 2025Article
- Chemical Composition and Biological Activities ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Mesoporous Silica Nanoparticle as a Potential Nanocarrier to Improve the Effectiveness of Antiobesity Drugs.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- The Patient's Journey in Obesity within the United States: An Exercise of Resilience against Disease.Life (Basel, Switzerland) · 2024Review
- Effective and appropriate use of weight loss medication in pediatric obesity: a narrative review.Journal of Yeungnam medical science · 2024Article
- Beyond the Cold: Activating Brown Adipose Tissue as an Approach to Combat Obesity.Journal of clinical medicine · 2024Review
- Patient and Healthcare Professional Preferences for Prescription Weight Loss Medications in Australia: Two Discrete Choice Experiments.Patient preference and adherence · 2024Article
- Pathophysiology of obesity and its associated diseases.Acta pharmaceutica Sinica. B · 2023Review
- Pharmacological Treatments and Natural Biocompounds in Weight Management.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Children (Basel, Switzerland) · 2023Review
- Natural products as novel anti-obesity agents: insights into mechanisms of action and potential for therapeutic management.Frontiers in pharmacology · 2023Review
- A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center.Obesity pillars · 2022Article
- Risk of Type 2 Diabetes Among Individuals with Excess Weight: Weight Trajectory Effects.Current diabetes reports · 2022Review
- Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health.Clinical liver disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionPharmacotherapy is a useful adjunct when patients with obesity are unable to achieve adequate benefit from lifestyle interventions. AREAS COVERED: This review covers the history of antiobesity drugs, efficacy, and risks of currently approved drugs, limits of their usefulness in clinical practice, gaps in knowledge, methodological limitations of clinical trials, and reasons for underutilization. EXPERT OPINION: In randomized controlled trials, currently approved antiobesity drugs have yielded an average weight loss ranging from approximately 3% to 9% relative to placebo at 1 year. Inadequate inclusion of racial and ethnic minorities and men, and high dropout rates in clinical trials limit generalizability of these findings to clinical practice. Weight loss achieved with antiobesity drugs is generally associated with lowered glycemia, but improvements in blood pressure and lipid measures tend to be marginal. There is limited evidence for sustained weight loss beyond 1 year and for safety and efficacy of antiobesity drugs in children and adolescents, and in post-bariatric surgery patients. None have demonstrated reduction in major adverse cardiovascular events or other significant disease outcomes. Limited health insurance coverage and negative perceptions of physicians have hindered the utilization of antiobesity drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.